Pharmaceutical Policies used in LMIC Countries to Enhance Pharmaceutical Spending Efficiency: A Review
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
University of the Western Cape
Abstract
Pharmaceutical spending makes up for a major share of healthcare costs in Low- and-Middle-
Income Countries (LMICs), where access to essential medicines is hindered by high prices,
inefficient procurement, and restricted budget. In order to achieve Universal Health Coverage
(UHC), there must be policies that ensure affordability and sustainability while addressing gaps
involving access to medicine.
This review aims to examine pharmaceutical policies implemented in selected LMICs to
enhance spending efficiency, focusing on cost-containment strategies, value-based pricing, and
Health Technology Assessment (HTA).
A systematic literature review was conducted using databases including PudMed, Scopus,
Google Scholar, ScienceDirect, SpringerLink, and Cochrane Library, covering studies
published between 2010 and 2023. The inclusion criteria used was peer-reviewed articles on
pharmaceutical policies in LMICs and the exclusion criteria used were studies unrelated to cos-
efficiency or outside the LMIC context. The data was synthesised thematically to identify
policy trends and gaps.
Three major themes emerged: (1) Cost-containment policies such as External Reference
Pricing (ERP), which are widely adopted in countries like Vietnam and Turkey, though
implementation challenges persist due to regulatory and resource constraints; (2) Cost-sharing
mechanisms, including co-payment, often reduce access for vulnerable populations despite
intended savings; (3) Value-based pricing and HTA are gaining traction, with South Africa and
Thailand showing progress, but institutionalisation remains limited. Generic medicine policies
significantly reduce costs, as seen in South Africa where generics account for over 65% of
market volume.
Tailored pharmaceutical policies can improve spending efficiency and equitable access in
LMICs. Measures such as strengthening HTA systems, promoting generics, and adopting
transparent pricing strategies are critical for sustainable UHC. This study recommends that
future research should focus on evaluating policy impact and developing context-specific
frameworks to guide implementation.